Takayoshi, Kotoe <br/><br/>
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Aug 2017 
 - 333-342 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-017-3371-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Capecitabine--administration & dosage<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Drug Combinations<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Intestinal Neoplasms--drug therapy<br/>Intestine, Small--pathology<br/>Japan<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Organoplatinum Compounds--administration & dosage<br/>Oxonic Acid--administration & dosage<br/>Retrospective Studies<br/>Survival Rate<br/>Tegafur--administration & dosage